Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (March 2004)
14 slides from Medical Developments International's investor presentation, Mar 17, 2004
Slide 1: Medical Developments International Limited Presentation March 2004
Medical Developments International Limited (“MDI” Presentation March 2004
Slide 2: Introduction
# Introduction = Methoxyflurane " Medical and Veterinary Equipment » Resources Next steps S is o fea nes o (oil c ® Z a. Q ey 8 _ CX) Ss © a QD oC 2 TS caby i = The following slides should be read in conjunction with Medical Developments International Limited Financial Report for the Half-Year Ended
Slide 3: Introduction - Products
Introduction - Products Analgesic for emergency pain relief (Penthrox Inhaler) =» Only manufacturer = Drug is TGA and Medsafe (NZ) approved = Plant is GMP Certified =» 48% of MDI sales =» Current Customers: + Australian Ambulance Services * Australian Defence Forces + Research Laboratories worldwide
Slide 4: Introduction - Products (Medical Equipment)
Introduction - Products c 2 fy cede oO Cc cea D os QD loss Cc [ay gg ® z o a 2 TS: QD Medical Equipment Key Products = Space Chambers (22% of sales) = Face masks (8% of sales) =» Peak Flow meters (4% of sales) = Oxygen Equipment (4% of sales) 30 devices registered with the TGA = Space Chambers and P
Slide 5: Introduction - Products (Veterinary Equipment)
Introduction - Products Veterinary Equipment =» Key Products = anaesthetic machines (6% of sales) = 66% of revenue from exports (oss 2 fy cede oO Co 4 See oO oo a Dn loss eo oO = ay gg © a o oS 2 ip @, i
Slide 6: Introduction: Business Performance is meeting expectations
Introduction Business Performance is meeting expectations Financial Performance = Underlying business is profitable with upside =» On track to meet or exceed the MDA proforma earnings pro-rata for FY2003 disclosed in the Prospectus Operations =» Smooth transition to a public company Increased produc
Slide 7: The timing of registration will determine growth
Methoxyflurane The timing of registration will determine growth c 2 fy cede oO (oil cea D es gQ Cc [ay gg ® z o oc 2 TS caby i = Registered in Australia and N.Z. = Registration requirements in other countries vary considerably: « Trial based * 2years + Potential to introduce during trials in some ju
Slide 8: In Australia and New Zealand, our goal is to generate sales this year
Methoxyflurane In Australia and New Zealand, our goal is to generate sales this year Australia = Used in: All ambulance services Defence forces «» Extreme sports « Use in hospitals is being trialled s Trials of alternatives not indicating any risk New Zealand = js, Qo fy cede o Co s S ® 2 =. Q ey 2
Slide 9: International Opportunities
Methoxyflurane International Opportunities North American registration will likely take 2 years, although there is potential for interim sales (oss 2 fy cede oO Co 4 & oO os a gL | eo ay gg © Ba o oS 2 TS caby i USA s USA Military application potential » FDA exemption possible s Registration support
Slide 10: International Opportunities
Methoxyflurane International Opportunities Registration in UK/Europe will likely take 2 years with limited/no scope for interim sales United Kingdom « Registration generally required before use; however exploring scope for non- registered distribution » Exploring interest in Ambulance and Military E
Slide 11: International Opportunities
Methoxyflurane International Opportunities South Africa and the Middle East will be priority markets given likely registration time frames South Africa, UAE, Singapore « Meetings with numerous parties: distributors, ambulance, hospitals and military = Strong interest in product « Various registratio
Slide 12: Medical and Veterinary Equipment
Medical and Veterinary Equipment We expect “double digit” growth in many market segments New Zealand » PHARMAC » Only subsidised Peak Flow Meter =» Expect “knock-on” sales for Spacers Europe =» Growth opportunities in anaesthetic machines and Breath Alert monitors Australia = Improve distribution to
Slide 13: Resources
Resources Key resources are being added to build marketing and production capabilities c 2 fy cede oO (oil cea D es gQ Cc [ay gg ® z o oc 2 TS caby i Marketing = Marketing documents on Methoxyflurane and Medical Equipment completed =» Appointments to be made shortly = Need to follow up on all opport
Slide 14: Next steps
Next steps «= Pursue Methoxyflurane sales in NZ (Ambulance and Defence) » Pursue registration in Asia and UAE/Middle East « Prioritise USA, Europe, UK and Canada based on ability to use/trial in parallel with registration » Pursue Aid Agencies » Pursue non-registered channel distribution » Finalise
Medical Developments International — Investor Presentation (March 2004) on 6ix